India
· Delayed Price · Currency is INR Valiant Laboratories Statistics
Total Valuation
Valiant Laboratories has a market cap or net worth of INR 4.95 billion. The enterprise value is 4.91 billion.
| Market Cap | 4.95B |
| Enterprise Value | 4.91B |
Important Dates
The next estimated earnings date is Tuesday, February 11, 2025.
| Earnings Date | Feb 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Valiant Laboratories has 43.45 million shares outstanding. The number of shares has increased by 6.57% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 43.45M |
| Shares Change (YoY) | +6.57% |
| Shares Change (QoQ) | +2.48% |
| Owned by Insiders (%) | 29.35% |
| Owned by Institutions (%) | 5.76% |
| Float | 8.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.43 |
| PB Ratio | 2.14 |
| P/TBV Ratio | 2.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -49.16 |
| EV / Sales | 4.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.60 |
Financial Position
The company has a current ratio of 8.76, with a Debt / Equity ratio of 0.50.
| Current Ratio | 8.76 |
| Quick Ratio | 6.75 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.32 |
| Interest Coverage | -224.37 |
Financial Efficiency
Return on equity (ROE) is -5.93% and return on invested capital (ROIC) is -5.36%.
| Return on Equity (ROE) | -5.93% |
| Return on Assets (ROA) | -4.78% |
| Return on Capital (ROIC) | -5.36% |
| Revenue Per Employee | 14.48M |
| Profits Per Employee | -1.30M |
| Employee Count | 77 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 7.94 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.34% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -36.34% |
| 50-Day Moving Average | 114.56 |
| 200-Day Moving Average | 132.38 |
| Relative Strength Index (RSI) | 45.29 |
| Average Volume (20 Days) | 305,484 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Valiant Laboratories had revenue of INR 1.11 billion and -99.93 million in losses. Loss per share was -2.30.
| Revenue | 1.11B |
| Gross Profit | -14.87M |
| Operating Income | -220.33M |
| Pretax Income | -116.82M |
| Net Income | -99.93M |
| EBITDA | -201.57M |
| EBIT | -220.33M |
| Loss Per Share | -2.30 |
Balance Sheet
The company has 1.19 billion in cash and 1.16 billion in debt, giving a net cash position of 33.95 million or 0.78 per share.
| Cash & Cash Equivalents | 1.19B |
| Total Debt | 1.16B |
| Net Cash | 33.95M |
| Net Cash Per Share | 0.78 |
| Equity (Book Value) | 2.32B |
| Book Value Per Share | 53.25 |
| Working Capital | 1.70B |
Cash Flow
In the last 12 months, operating cash flow was 162.08 million and capital expenditures -1.04 billion, giving a free cash flow of -876.78 million.
| Operating Cash Flow | 162.08M |
| Capital Expenditures | -1.04B |
| Free Cash Flow | -876.78M |
| FCF Per Share | -20.18 |
Margins
Gross margin is -1.33%, with operating and profit margins of -19.77% and -8.96%.
| Gross Margin | -1.33% |
| Operating Margin | -19.77% |
| Pretax Margin | -10.48% |
| Profit Margin | -8.96% |
| EBITDA Margin | -18.08% |
| EBIT Margin | -19.77% |
| FCF Margin | n/a |
Dividends & Yields
Valiant Laboratories does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.57% |
| Shareholder Yield | -6.57% |
| Earnings Yield | -2.02% |
| FCF Yield | -17.73% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |